Literature DB >> 23997778

Point prevalence study of antibiotic susceptibility of genital group B streptococcus isolated from near-term pregnant women in Calgary, Alberta.

Deirdre Church1, Julie Carson, Dan Gregson.   

Abstract

BACKGROUND: Genital group B streptococcus (GBS) may be transmitted from a colonized mother to her infant if appropriate intrapartum antibiotic prophylaxis is not given. A recent case of GBS neonatal sepsis occurred due to an erythromycin-intermediate strain after empirical use of this drug as intrapartum prophylaxis.
OBJECTIVE: To determine the regional antibiotic resistance rates of genital GBS isolates to penicillin, erythromycin and clindamycin.
METHODS: A total of 309 genital GBS strains cultured from vaginal/rectal swabs were prospectively isolated and randomly selected between March and May 2011. Etest strips (bioMèrieux, France) were used to determine the minimum inhibitory concentrations to penicillin, erythromycin and clindamycin according to standard methods. All isolates that either demonstrated intermediate or full resistance to erythromycin had a D-test performed to detect inducible resistance to clindamycin. The resistance mechanism for each isolate was inferred from its antibiogram phenotype.
RESULTS: All genital GBS isolates were susceptible to penicillin, but high rates of resistance were found to both erythromycin (25%) and clindamycin (22%), mainly due to acquisition of erythromycin ribosomal methylation genes (erm) that result in the MLSB resistance phenotype. Most often the MLSB resistance phenotype was constitutive (MLSB-C; 14.2%) rather than inducible (MLSB-I; 8.1%), and an efflux mechanism (msrA; 3%) was much less common. DISCUSSION: The present article is the first point prevalence study of genital GBS antibiogram profile that has been reported from a Canadian health care region. The high rates of resistance of genital GBS to both erythromycin and clindamycin is mainly due to the acquisition and spread of erm genes conveying the MSLB phenotype.
CONCLUSION: Changes to clinical and laboratory practice in the Calgary, Alberta, region were made to prevent additional cases of neonatal GBS sepsis due to inappropriate intrapartum antibiotic prescription.

Entities:  

Keywords:  Antibiotic resistance; Group B streptococcus; Neonatal sepsis

Year:  2012        PMID: 23997778      PMCID: PMC3476555          DOI: 10.1155/2012/876103

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  27 in total

1.  Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.

Authors:  Barbara J Stoll; Nellie I Hansen; Pablo J Sánchez; Roger G Faix; Brenda B Poindexter; Krisa P Van Meurs; Matthew J Bizzarro; Ronald N Goldberg; Ivan D Frantz; Ellen C Hale; Seetha Shankaran; Kathleen Kennedy; Waldemar A Carlo; Kristi L Watterberg; Edward F Bell; Michele C Walsh; Kurt Schibler; Abbot R Laptook; Andi L Shane; Stephanie J Schrag; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2011-04-25       Impact factor: 7.124

2.  [High resistance of bacterial strains Streptococcus agalactiae to antibiotic therapy in early-onset and late-onset disease in newborns].

Authors:  D Balíková; V Adámková; J Svobodová
Journal:  Ceska Gynekol       Date:  2011-06

3.  High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus.

Authors:  Linda P DiPersio; Joseph R DiPersio
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01       Impact factor: 2.803

4.  Neonatal infections in England: the NeonIN surveillance network.

Authors:  Stefania Vergnano; Esse Menson; Nigel Kennea; Nick Embleton; Alison Bedford Russell; Timothy Watts; Michael J Robinson; Andrew Collinson; Paul T Heath
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2010-09-27       Impact factor: 5.747

5.  Prevention of Group B Streptococcus early-onset disease: a toolkit by the California Perinatal Quality Care Collaborative.

Authors:  R J Powers; D Wirtschafter
Journal:  J Perinatol       Date:  2009-08-06       Impact factor: 2.521

6.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.

Authors:  S J Schrag; S Zywicki; M M Farley; A L Reingold; L H Harrison; L B Lefkowitz; J L Hadler; R Danila; P R Cieslak; A Schuchat
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

Review 7.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.

Authors:  Roland Leclercq
Journal:  Clin Infect Dis       Date:  2002-01-11       Impact factor: 9.079

Review 8.  Group B streptococcal disease in infants: progress in prevention and continued challenges.

Authors:  Jennifer R Verani; Stephanie J Schrag
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

Review 9.  Duration of intrapartum prophylaxis for neonatal group B streptococcal disease: a systematic review.

Authors:  Jessica L Illuzzi; Michael B Bracken
Journal:  Obstet Gynecol       Date:  2006-11       Impact factor: 7.661

10.  Prevalence and mechanisms of erythromycin resistance in Streptococcus agalactiae from healthy pregnant women.

Authors:  Sandra Pinheiro; Hajer Radhouani; Céline Coelho; Alexandre Gonçalves; Eulália Carvalho; José António Carvalho; Fernanda Ruiz-Larrea; Carmen Torres; Gilberto Igrejas; Patrícia Poeta
Journal:  Microb Drug Resist       Date:  2009-06       Impact factor: 3.431

View more
  4 in total

1.  Evaluation of StrepBSelect Chromogenic Medium and the Fast-Track Diagnostics Group B Streptococcus (GBS) Real-Time PCR Assay Compared to Routine Culture for Detection of GBS during Antepartum Screening.

Authors:  Deirdre L Church; Heather Baxter; Tracie Lloyd; Oscar Larios; Daniel B Gregson
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

2.  Evaluation of Culture, Antigen Detection and Polymerase Chain Reaction for Detection of Vaginal Colonization of Group B Streptococcus (GBS) in Pregnant Women.

Authors:  Kavitha Paul Konikkara; Shrikala Baliga; Suchithra Shenoy; B Bharati
Journal:  J Clin Diagn Res       Date:  2014-02-03

3.  The draft genomes and investigation of serotype distribution, antimicrobial resistance of group B Streptococcus strains isolated from urine in Suzhou, China.

Authors:  Yong Guo; Xiao Deng; Yuan Liang; Liang Zhang; Guo-Ping Zhao; Yan Zhou
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-06-26       Impact factor: 3.944

4.  Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Authors:  Kate Skolnik; Austin Nguyen; Christina S Thornton; Barbara Waddell; Tyler Williamson; Harvey R Rabin; Michael D Parkins
Journal:  BMC Infect Dis       Date:  2017-10-02       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.